Blog
About

19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

      Nature reviews. Drug discovery

      therapeutic use, drug effects, RNA, Untranslated, drug therapy, Neoplasms, methods, Molecular Targeted Therapy, Models, Biological, MicroRNAs, Humans, Drug Discovery, pharmacology, Antineoplastic Agents

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The first cancer-targeted microRNA (miRNA) drug - MRX34, a liposome-based miR-34 mimic - entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.

          Related collections

          Author and article information

          Journal
          24172333
          10.1038/nrd4140

          Comments

          Comment on this article